Palatin Reports Third Quarter Fiscal Year 2022 Financial Results and Provides Corporate Update

Patient Enrollment on Track in Phase 3 Pivotal Study of PL9643 in Patients with Dry Eye Disease with Topline Results Currently Expected Second Half Calendar...

Related Keywords

United States ,Washington ,American ,Carl Spana ,Exchange Commission ,Palatin Technologies Inc ,Prnewswire Palatin Technologies Inc ,Securities Exchange ,Association For Research ,Colitis Congress ,Patient Enrollment ,Dry Eye Disease ,Private Placement ,Convertible Redeemable Preferred Stock ,Ulcerative Colitis Expected ,Start Next Month ,Quarter Ended Fiscal Year ,Hypoactive Sexual Desire Disorder ,Key Opinion Leader ,Seriesb Convertible Redeemable Preferred Stock ,Seriesc Convertible Redeemable Preferred Stock ,Seriesb Preferred Stock ,Seriesc Preferred Stock ,United States Securities ,Fiscal Quarter Ended March ,Termination Agreement ,Preferred Stock ,Melanocortin Receptor Agonists ,Palatin Technologies ,Securities Act ,Securities Exchange Act ,Private Securities Litigation Reform Act ,Months Ended March ,Nc ,